James E Flynn Insider Trading Transactions
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
Latest Insider Trading Transactions of James E Flynn
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 04 2021 | HOWL | Werewolf Therapeut ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 15,195,094 | 0 | 0 | |
May 04 2021 | HOWL | Werewolf Therapeut ... | Flynn James E | 10% Owner | Buy | P | 16.00 | 800,000 | 12,800,000 | 2,552,787 | 1.8 M to 2.6 M (+45.64 %) |
May 04 2021 | HOWL | Werewolf Therapeut ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 1,752,787 | 0 | 1,752,787 | 0 to 1.8 M |
Mar 30 2021 | EWTX | Edgewise Therapeut ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 433,551 | 0 | 0 | |
Mar 30 2021 | EWTX | Edgewise Therapeut ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 1,301,626 | 0 | 0 | |
Mar 30 2021 | EWTX | Edgewise Therapeut ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 1,572,960 | 0 | 0 | |
Mar 30 2021 | EWTX | Edgewise Therapeut ... | Flynn James E | 10% Owner | Buy | P | 16.00 | 625,000 | 10,000,000 | 3,933,137 | 3.3 M to 3.9 M (+18.89 %) |
Mar 30 2021 | EWTX | Edgewise Therapeut ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 433,551 | 0 | 3,308,137 | 2.9 M to 3.3 M (+15.08 %) |
Mar 30 2021 | EWTX | Edgewise Therapeut ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 1,301,626 | 0 | 2,874,586 | 1.6 M to 2.9 M (+82.75 %) |
Mar 30 2021 | EWTX | Edgewise Therapeut ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 1,572,960 | 0 | 1,572,960 | 0 to 1.6 M |
Feb 09 2021 | TERN | Terns Pharmaceutic ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 1,717,033 | 0 | 0 | |
Feb 09 2021 | TERN | Terns Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 665,000 | 11,305,000 | 2,382,033 | 1.7 M to 2.4 M (+38.73 %) |
Feb 09 2021 | TERN | Terns Pharmaceutic ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 1,717,033 | 0 | 1,717,033 | 0 to 1.7 M |
Jan 08 2021 | NLNK | LUMOS PHARMA, INC. | Flynn James E | 10% Owner | Sell | S | 22.24 | 101,600 | 2,259,797 | 784,568 | 886.2 K to 784.6 K (-11.47 %) |
Jan 08 2021 | NLNK | LUMOS PHARMA, INC. | Flynn James E | 10% Owner | Sell | S | 23.57 | 3,912 | 92,194 | 886,168 | 890.1 K to 886.2 K (-0.44 %) |
Jan 08 2021 | NLNK | LUMOS PHARMA, INC. | Flynn James E | 10% Owner | Sell | S | 24.11 | 1,000 | 24,108 | 890,080 | 891.1 K to 890.1 K (-0.11 %) |
Jan 08 2021 | NLNK | LUMOS PHARMA, INC. | Flynn James E | 10% Owner | Sell | S | 25.05 | 4,378 | 109,665 | 891,080 | 895.5 K to 891.1 K (-0.49 %) |
Jan 08 2021 | NLNK | LUMOS PHARMA, INC. | Flynn James E | 10% Owner | Sell | S | 24.35 | 11,794 | 287,157 | 895,458 | 907.3 K to 895.5 K (-1.30 %) |
Jan 08 2021 | NLNK | LUMOS PHARMA, INC. | Flynn James E | 10% Owner | Sell | S | 22.64 | 931 | 21,082 | 907,252 | 908.2 K to 907.3 K (-0.10 %) |
Jan 08 2021 | NLNK | LUMOS PHARMA, INC. | Flynn James E | 10% Owner | Sell | S | 22.47 | 28,108 | 631,620 | 908,183 | 936.3 K to 908.2 K (-3.00 %) |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 2,449,761 | 0 | 0 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 2,449,761 | 0 | 0 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 2,449,761 | 0 | 0 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 7,499,999 | 0 | 0 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 7,499,999 | 0 | 0 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | P | 15.00 | 109,612 | 1,644,180 | 312,282 | 202.7 K to 312.3 K (+54.08 %) |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | P | 15.00 | 445,194 | 6,677,910 | 1,268,344 | 823.2 K to 1.3 M (+54.08 %) |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | P | 15.00 | 445,194 | 6,677,910 | 1,268,344 | 823.2 K to 1.3 M (+54.08 %) |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 202,670 | 0 | 202,670 | 0 to 202.7 K |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 202,670 | 0 | 823,150 | 620.5 K to 823.2 K (+32.66 %) |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 202,670 | 0 | 823,150 | 620.5 K to 823.2 K (+32.66 %) |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 620,480 | 0 | 620,480 | 0 to 620.5 K |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 620,480 | 0 | 620,480 | 0 to 620.5 K |
Aug 12 2020 | AFIB | Acutus Medical, In ... | Flynn James E | Director | Option Exercise | C | 0.00 | 1,002,464 | 0 | 0 | |
Aug 12 2020 | AFIB | Acutus Medical, In ... | Flynn James E | Director | Option Exercise | C | 0.00 | 189,366 | 0 | 0 | |
Aug 12 2020 | AFIB | Acutus Medical, In ... | Flynn James E | Director | Option Exercise | C | 0.00 | 1,199,980 | 0 | 0 | |
Aug 12 2020 | AFIB | Acutus Medical, In ... | Flynn James E | Director | Option Exercise | C | 0.00 | 449,992 | 0 | 0 | |
Aug 12 2020 | AFIB | Acutus Medical, In ... | Flynn James E | Director | Option Exercise | A | 18.00 | 12,454 | 224,172 | 12,454 | |
Aug 12 2020 | AFIB | Acutus Medical, In ... | Flynn James E | Director | Buy | P | 18.00 | 555,556 | 10,000,008 | 2,758,000 | 2.2 M to 2.8 M (+25.22 %) |
Aug 12 2020 | AFIB | Acutus Medical, In ... | Flynn James E | Director | Buy | P | 18.00 | 944,444 | 16,999,992 | 1,583,802 | 639.4 K to 1.6 M (+147.72 %) |
Aug 12 2020 | AFIB | Acutus Medical, In ... | Flynn James E | Director | Buy | C | 0.00 | 1,002,464 | 0 | 2,202,444 | 1.2 M to 2.2 M (+83.54 %) |
Aug 12 2020 | AFIB | Acutus Medical, In ... | Flynn James E | Director | Buy | C | 0.00 | 189,366 | 0 | 639,358 | 450 K to 639.4 K (+42.08 %) |
Aug 12 2020 | AFIB | Acutus Medical, In ... | Flynn James E | Director | Buy | C | 0.00 | 1,199,980 | 0 | 1,199,980 | 0 to 1.2 M |
Aug 12 2020 | AFIB | Acutus Medical, In ... | Flynn James E | Director | Buy | C | 0.00 | 449,992 | 0 | 449,992 | 0 to 450 K |
Aug 12 2020 | AFIB | Acutus Medical, In ... | Flynn James E | Director | Grant | A | 0.00 | 2,222 | 0 | 2,222 | 0 to 2.2 K |
Jul 28 2020 | ANNX | Annexon, Inc. | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 4,043,031 | 0 | 0 | |
Jul 28 2020 | ANNX | Annexon, Inc. | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 4,043,032 | 0 | 0 | |
Jul 28 2020 | ANNX | Annexon, Inc. | Flynn James E | 10% Owner | Buy | P | 17.00 | 350,000 | 5,950,000 | 808,914 | 458.9 K to 808.9 K (+76.27 %) |
Jul 28 2020 | ANNX | Annexon, Inc. | Flynn James E | 10% Owner | Buy | P | 17.00 | 350,000 | 5,950,000 | 808,914 | 458.9 K to 808.9 K (+76.27 %) |
Jul 28 2020 | ANNX | Annexon, Inc. | Flynn James E | 10% Owner | Buy | C | 0.00 | 458,914 | 0 | 458,914 | 0 to 458.9 K |
Jul 28 2020 | ANNX | Annexon, Inc. | Flynn James E | 10% Owner | Buy | C | 0.00 | 458,914 | 0 | 458,914 | 0 to 458.9 K |
Jul 22 2020 | DFHT | Deerfield Healthca ... | Flynn James E | Director | Buy | J | 10.00 | 3,360,000 | 33,600,000 | 3,360,000 | 0 to 3.4 M |
Jul 14 2020 | NKTX | Nkarta, Inc. | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 2,626,767 | 0 | 0 | |
Jul 14 2020 | NKTX | Nkarta, Inc. | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 2,626,767 | 0 | 0 | |
Jul 14 2020 | NKTX | Nkarta, Inc. | Flynn James E | 10% Owner | Buy | P | 18.00 | 500,000 | 9,000,000 | 1,209,936 | 709.9 K to 1.2 M (+70.43 %) |
Jul 14 2020 | NKTX | Nkarta, Inc. | Flynn James E | 10% Owner | Buy | P | 18.00 | 500,000 | 9,000,000 | 1,209,936 | 709.9 K to 1.2 M (+70.43 %) |
Jul 14 2020 | NKTX | Nkarta, Inc. | Flynn James E | 10% Owner | Buy | C | 0.00 | 709,936 | 0 | 709,936 | 0 to 709.9 K |
Jul 14 2020 | NKTX | Nkarta, Inc. | Flynn James E | 10% Owner | Buy | C | 0.00 | 709,936 | 0 | 709,936 | 0 to 709.9 K |
Jun 16 2020 | GBIO | Generation Bio Co. | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 455,500 | 0 | 0 | |
Jun 16 2020 | GBIO | Generation Bio Co. | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 1,093,410 | 0 | 0 | |
Jun 16 2020 | GBIO | Generation Bio Co. | Flynn James E | 10% Owner | Buy | P | 19.00 | 225,000 | 4,275,000 | 1,186,215 | 961.2 K to 1.2 M (+23.41 %) |
Jun 16 2020 | GBIO | Generation Bio Co. | Flynn James E | 10% Owner | Buy | C | 0.00 | 257,883 | 0 | 961,215 | 703.3 K to 961.2 K (+36.67 %) |
Jun 16 2020 | GBIO | Generation Bio Co. | Flynn James E | 10% Owner | Buy | C | 0.00 | 703,332 | 0 | 703,332 | 0 to 703.3 K |
Mar 17 2020 | DFPH | DFP HEALTHCARE ACQ ... | Flynn James E | Director | Buy | J | 10.00 | 2,500,000 | 25,000,000 | 2,500,000 | 0 to 2.5 M |
Mar 17 2020 | DFPH | DFP HEALTHCARE ACQ ... | Flynn James E | Director | Buy | J | 10.00 | 2,500,000 | 25,000,000 | 2,500,000 | 0 to 2.5 M |
Feb 18 2020 | RVMD | Revolution Medicin ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 498,795 | 0 | 0 | |
Feb 18 2020 | RVMD | Revolution Medicin ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 997,589 | 0 | 0 | |
Feb 18 2020 | RVMD | Revolution Medicin ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 300,000 | 5,100,000 | 798,795 | 498.8 K to 798.8 K (+60.14 %) |
Feb 18 2020 | RVMD | Revolution Medicin ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 300,000 | 5,100,000 | 1,297,589 | 997.6 K to 1.3 M (+30.07 %) |
Feb 18 2020 | RVMD | Revolution Medicin ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 498,795 | 0 | 498,795 | 0 to 498.8 K |
Feb 18 2020 | RVMD | Revolution Medicin ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 997,589 | 0 | 997,589 | 0 to 997.6 K |
Feb 10 2020 | SDGR | Schrodinger, Inc. | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 10,063,061 | 0 | 0 | |
Feb 10 2020 | SDGR | Schrodinger, Inc. | Flynn James E | 10% Owner | Buy | P | 17.00 | 250,000 | 4,250,000 | 250,000 | 0 to 250 K |
Feb 10 2020 | SDGR | Schrodinger, Inc. | Flynn James E | 10% Owner | Buy | C | 0.00 | 1,346,167 | 0 | 1,346,167 | 0 to 1.3 M |
Feb 03 2020 | BDTX | Black Diamond Ther ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 1,142,361 | 0 | 0 | |
Feb 03 2020 | BDTX | Black Diamond Ther ... | Flynn James E | 10% Owner | Buy | P | 19.00 | 400,000 | 7,600,000 | 778,790 | 378.8 K to 778.8 K (+105.60 %) |
Feb 03 2020 | BDTX | Black Diamond Ther ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 378,790 | 0 | 378,790 | 0 to 378.8 K |
Jan 31 2020 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 15.45 | 509,970 | 7,879,037 | 0 | 510 K to 0 (-100.00 %) |
Jan 31 2020 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 15.45 | 8,857 | 136,808 | 509,970 | 518.8 K to 510 K (-1.71 %) |
Jan 28 2020 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 15.51 | 65,891 | 1,021,936 | 518,827 | 584.7 K to 518.8 K (-11.27 %) |
Jan 28 2020 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 15.77 | 193,359 | 3,049,600 | 584,718 | 778.1 K to 584.7 K (-24.85 %) |
Jan 28 2020 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 15.69 | 380,256 | 5,965,000 | 778,077 | 1.2 M to 778.1 K (-32.83 %) |
Dec 27 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.95 | 151,233 | 3,319,579 | 1,766,106 | 1.9 M to 1.8 M (-7.89 %) |
Dec 27 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.95 | 198,767 | 4,362,956 | 2,321,199 | 2.5 M to 2.3 M (-7.89 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.83 | 56,595 | 1,235,435 | 1,917,339 | 2 M to 1.9 M (-2.87 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.83 | 74,384 | 1,623,758 | 2,519,966 | 2.6 M to 2.5 M (-2.87 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.50 | 9,130 | 196,297 | 1,973,934 | 2 M to 2 M (-0.46 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.50 | 11,999 | 257,981 | 2,594,350 | 2.6 M to 2.6 M (-0.46 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.68 | 5,454 | 118,219 | 1,983,064 | 2 M to 2 M (-0.27 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.68 | 7,168 | 155,371 | 2,606,349 | 2.6 M to 2.6 M (-0.27 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.83 | 56,595 | 1,235,435 | 1,917,339 | 2 M to 1.9 M (-2.87 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.83 | 74,384 | 1,623,758 | 2,519,966 | 2.6 M to 2.5 M (-2.87 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.50 | 9,130 | 196,297 | 1,973,934 | 2 M to 2 M (-0.46 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.50 | 11,999 | 257,981 | 2,594,350 | 2.6 M to 2.6 M (-0.46 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.68 | 5,454 | 118,219 | 1,983,064 | 2 M to 2 M (-0.27 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.68 | 7,168 | 155,371 | 2,606,349 | 2.6 M to 2.6 M (-0.27 %) |
Nov 13 2019 | DFBH | AdaptHealth Corp. | Flynn James E | Director | Option Exercise | J | 11.50 | 460,685 | 5,297,878 | 1,640,981 | |
Nov 13 2019 | DFBH | AdaptHealth Corp. | Flynn James E | Director | Option Exercise | J | 11.50 | 460,685 | 5,297,878 | 1,640,981 | |
Nov 13 2019 | DFBH | AdaptHealth Corp. | Flynn James E | Director | Sell | J | 0.00 | 6,087 | 0 | 20,000 | 26.1 K to 20 K (-23.33 %) |
Nov 13 2019 | DFBH | AdaptHealth Corp. | Flynn James E | Director | Sell | J | 0.00 | 6,087 | 0 | 20,000 | 26.1 K to 20 K (-23.33 %) |
Nov 13 2019 | DFBH | AdaptHealth Corp. | Flynn James E | Director | Sell | J | 0.00 | 652,253 | 0 | 2,279,888 | 2.9 M to 2.3 M (-22.24 %) |
Nov 13 2019 | DFBH | AdaptHealth Corp. | Flynn James E | Director | Sell | J | 0.00 | 652,253 | 0 | 2,279,888 | 2.9 M to 2.3 M (-22.24 %) |
Nov 13 2019 | DFBH | AdaptHealth Corp. | Flynn James E | Director | Grant | A | 10.00 | 12,400,000 | 124,000,000 | 14,900,000 | 2.5 M to 14.9 M (+496.00 %) |
Nov 13 2019 | DFBH | AdaptHealth Corp. | Flynn James E | Director | Grant | A | 10.00 | 12,400,000 | 124,000,000 | 14,900,000 | 2.5 M to 14.9 M (+496.00 %) |
Oct 30 2019 | CABA | Cabaletta Bio, Inc ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 696,379 | 0 | 0 | |
Oct 30 2019 | CABA | Cabaletta Bio, Inc ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 696,379 | 0 | 0 | |
Oct 30 2019 | CABA | Cabaletta Bio, Inc ... | Flynn James E | 10% Owner | Buy | P | 11.00 | 700,000 | 7,700,000 | 700,000 | 0 to 700 K |
Oct 30 2019 | CABA | Cabaletta Bio, Inc ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 464,253 | 0 | 464,253 | 0 to 464.3 K |
Oct 30 2019 | CABA | Cabaletta Bio, Inc ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 464,253 | 0 | 464,253 | 0 to 464.3 K |
Oct 07 2019 | FREQ | Frequency Therapeu ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 3,184,948 | 0 | 0 | |
Oct 07 2019 | FREQ | Frequency Therapeu ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 3,184,948 | 0 | 0 | |
Oct 07 2019 | FREQ | Frequency Therapeu ... | Flynn James E | 10% Owner | Buy | P | 14.00 | 285,714 | 3,999,996 | 285,714 | 0 to 285.7 K |
Oct 07 2019 | FREQ | Frequency Therapeu ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 472,860 | 0 | 472,860 | 0 to 472.9 K |
Oct 07 2019 | FREQ | Frequency Therapeu ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 472,860 | 0 | 472,860 | 0 to 472.9 K |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 12,467,650 | 0 | 0 | |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 12,467,650 | 0 | 0 | |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 15.00 | 166,000 | 2,490,000 | 166,000 | 0 to 166 K |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 15.00 | 166,000 | 2,490,000 | 1,724,456 | 1.6 M to 1.7 M (+10.65 %) |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 1,558,456 | 0 | 1,558,456 | 0 to 1.6 M |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 1,558,456 | 0 | 1,558,456 | 0 to 1.6 M |
Jul 01 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 2.69 | 590,801 | 1,589,668 | 3,159,165 | 3.7 M to 3.2 M (-15.75 %) |
Jul 01 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 2.69 | 108,674 | 292,409 | 964,101 | 1.1 M to 964.1 K (-10.13 %) |
Jun 26 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.50 | 1,352 | 6,086 | 3,749,966 | 3.8 M to 3.7 M (-0.04 %) |
Jun 26 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.50 | 352 | 1,585 | 1,072,775 | 1.1 M to 1.1 M (-0.03 %) |
Jun 25 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.51 | 40,850 | 184,189 | 3,751,318 | 3.8 M to 3.8 M (-1.08 %) |
Jun 25 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.51 | 10,634 | 47,948 | 1,073,127 | 1.1 M to 1.1 M (-0.98 %) |
Jun 25 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.52 | 50,177 | 226,925 | 3,792,168 | 3.8 M to 3.8 M (-1.31 %) |
Jun 25 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.52 | 13,063 | 59,077 | 1,083,761 | 1.1 M to 1.1 M (-1.19 %) |
Jun 25 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.62 | 269,402 | 1,243,398 | 3,842,345 | 4.1 M to 3.8 M (-6.55 %) |
Jun 25 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 4.62 | 70,135 | 323,701 | 1,096,824 | 1.2 M to 1.1 M (-6.01 %) |
Jun 11 2019 | FIXX | Homology Medicines ... | Flynn James E | Director | Option Exercise | A | 19.51 | 15,580 | 303,966 | 15,580 | |
May 13 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 6.05 | 71,869 | 434,750 | 1,166,959 | 1.2 M to 1.2 M (-5.80 %) |
May 13 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 6.05 | 108,696 | 657,524 | 4,111,747 | 4.2 M to 4.1 M (-2.58 %) |
May 13 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 6.16 | 172,800 | 1,064,016 | 1,238,828 | 1.4 M to 1.2 M (-12.24 %) |
May 13 2019 | ACRS | Aclaris Therapeuti ... | Flynn James E | 10% Owner | Sell | S | 6.16 | 261,345 | 1,609,232 | 4,220,443 | 4.5 M to 4.2 M (-5.83 %) |
Apr 15 2019 | FIXX | Homology Medicines ... | Flynn James E | Director | Buy | P | 22.50 | 533,333 | 11,999,993 | 1,158,333 | 625 K to 1.2 M (+85.33 %) |
Mar 11 2019 | SWAV | ShockWave Medical, ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 284,659 | 0 | 0 | |
Mar 11 2019 | SWAV | ShockWave Medical, ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 1,619,433 | 0 | 0 | |
Mar 11 2019 | SWAV | ShockWave Medical, ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 284,659 | 0 | 0 | |
Mar 11 2019 | SWAV | ShockWave Medical, ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 1,619,433 | 0 | 0 | |
Mar 11 2019 | SWAV | ShockWave Medical, ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 10,000 | 170,000 | 10,000 | 0 to 10 K |
Mar 11 2019 | SWAV | ShockWave Medical, ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 10,000 | 170,000 | 166,073 | 156.1 K to 166.1 K (+6.41 %) |
Mar 11 2019 | SWAV | ShockWave Medical, ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 10,000 | 170,000 | 166,073 | 156.1 K to 166.1 K (+6.41 %) |
Mar 11 2019 | SWAV | ShockWave Medical, ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 23,333 | 0 | 156,073 | 132.7 K to 156.1 K (+17.58 %) |
Mar 11 2019 | SWAV | ShockWave Medical, ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 132,740 | 0 | 132,740 | 0 to 132.7 K |
Mar 11 2019 | SWAV | ShockWave Medical, ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 23,333 | 0 | 156,073 | 132.7 K to 156.1 K (+17.58 %) |
Mar 11 2019 | SWAV | ShockWave Medical, ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 132,740 | 0 | 132,740 | 0 to 132.7 K |
Feb 12 2019 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 15.00 | 1,351 | 20,265 | 856,470 | 857.8 K to 856.5 K (-0.16 %) |
Feb 12 2019 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 15.11 | 5,890 | 88,986 | 857,821 | 863.7 K to 857.8 K (-0.68 %) |
Feb 07 2019 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 15.00 | 9,409 | 141,135 | 863,711 | 873.1 K to 863.7 K (-1.08 %) |